Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer

Affiliations

¹ Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias i Pujol, Badalona 08916, Spain; Universitat Autónoma de Barcelona, Barcelona, Spain. Electronic address: rrosell@iconcologia.net.
² Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias i Pujol, Badalona 08916, Spain; Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Comment

Rafael Rosell et al. Lancet Oncol. 2020 Jun.

. 2020 Jun;21(6):736-738.

doi: 10.1016/S1470-2045(20)30146-7. Epub 2020 May 7.

¹ Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias i Pujol, Badalona 08916, Spain; Universitat Autónoma de Barcelona, Barcelona, Spain. Electronic address: rrosell@iconcologia.net.
² Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias i Pujol, Badalona 08916, Spain; Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

No abstract available

Comment on

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, Garofano RF, Stoopler MB, Cheng SK, White A, Lanuti M, D'Ovidio F, Bacchetta M, Sonett JR, Saqi A, Rizvi NA. Shu CA, et al. Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7. Lancet Oncol. 2020. PMID: 32386568 Clinical Trial.